ral role in infection and pathogenesis. These proteins should be considered in elucidation of the steps involved in infection, design of vaccines, preparation of experimental virus-challenge stocks, and determination of the pathological mechanisms of immunodeficiency viruses. 20 (5) . Apparently, an immune response to some cellular antigen or antigens is critical for this protection. The inactivated whole virus vaccine approach has been largely unsuccessful against SIV grown in rhesus monkey lymphocytes (6, 7) . Priming with vaccinia recombinants followed by boosting has protected rhesus monkeys against challenge by homologous cloned SIV (8) , but little or no protection has been observed against homologous uncloned SIV (9) (10) (11) (12) . What is most disappointing about these studies is that the numerous failures have occurred despite extensive efforts to maximize, in an unrealistic fashion, the likelihood of vaccine protection. The vast majority of studies have used a minimal dose of challenge virus, matched to the strain used for vaccination, at or near the peak of vaccine-induced immune response.
We investigated an approach that uses live attenuated SIV as a vaccine. Six rhesus monkeys that were infected with cloned SIVmac239 that contained a constructed deletion in the auxiliary gene nef have maintained extremely low virus burdens and normal CD4' lymphocyte concentrations and have remained healthy for more than 3 years after experimental inoculation with the mutated virus (13, 14) . Eleven of twelve rhesus monkeys infected with wildtype SIV in parallel have died over this same period. The rhesus monkeys infected with SIVmac239/nef-deletion have shown no clinical signs whatsoever over the entire period of observation.
Four of the rhesus monkeys infected with nef-deleted SIV were challenged with (17), and aliquots of the frozen virus stocks were carefully titered in rhesus monkeys before the challenge experiment (18) . In both cases, ten rhesus monkey infectious doses were used for the challenge. Neutralizing antibody titers on the day of challenge ranged from 1:320 to 1:2560 in the four rhesus monkeys previously vaccinated with live nef-deletion virus (Table 1) . Virus loads, measured by limiting dilution co-culture and semiquantitative polymerase chain reaction (PCR) (13, 14), were extremely low before challenge. We were unable to recover SIV from 106 PBMCs of the four rhesus monkeys on the day of challenge (Table 1) . Two naive rhesus monkeys served as controls for each of the challenge viruses. Several parameters were monitored for evidence of protection against the challenge viruses. All four control monkeys showed a spike of plasma antigenemia 2 weeks after challenge, as we have always seen previously with infection by these viruses (Table 2) . In some cases, the plasma antigenemia persisted and in others it dipped below detectable levels only to reappear at a later time. No plasma antigenemia was detected at any time in any of the four previously vaccinated monkeys (Table   2) .
We also evaluated virus loads by measuring the numbers of PBMCs required to recover SIV by limiting dilution co-culture. All four unvaccinated control monkeys exhibited high virus burdens, as we have always seen previously with infection by these wild-type viruses (Table 3) . Generally, 1,000 to 20,000 PBMCs were needed for SIV recovery from the control animals. One test monkey, 397-88, showed a spike in virus recovery at 4 weeks after the challenge in that SIV was recovered with 74,000 or more PBMCs. SIV sequences present in the vaccine strain (Fig. 1A) . Sequence analysis of this product revealed deletion of base pairs 9251 to 9432, which are the sequences in nef deleted in the vaccine strain, as well as deletions of base pairs 9476 to 9586 and 9650 to 9800. Thus, SIV recovered from animal 255-88 at weeks 12, 24, and 31 after challenge contained the original deletion present in the vaccine strain plus additional deletions in the region of the nef gene that overlaps the right long terminal repeat. The polypurine tract, the NF-KB binding site, and the Spl binding sites, critical for virus replication, were all retained in this virus. The important point is that we were not able to detect any of the wild-type nef-open viral sequences in the recovered SIV either by ethidium bromide staining of the amplified products (Fig. 1A) or by Southern (DNA) blot hybridization of the products (Fig. 1B) . The detection of DNA sequences directly from PBMCs required sensitive amplification procedures because of the extremely low virus burdens present in the vaccinated and challenged monkeys. We were able to amplify DNA sequences directly from the PBMCs of all four test animals by using a PCR amplification protocol that included both nested reactions (20, 21) and turboboosting (22) (Fig. 2) . Negative control DNA prepared at the same time tested negative for the presence of viral DNA sequences. Multiple PCR reactions were performed with PBMC DNA samples taken from each test animal 36 and 40 weeks after challenge; five or more PCR reactions were performed with at least one DNA sample from each animal. Viral DNA was detected in nine out of nine amplifications from animal 71-88 and in five out of seven amplifications from animal 397-88, and the amplified product in all cases except one corresponded to the nef-deletion used originally for vaccination. Viral DNA in the one exception contained the original deletion in nef plus an additional 138-bp deletion. Viral DNA was also detected in 15 out of 15 amplifications from the PBMCs of animal 255-88. The predominant product from the PBMCs of animal 255-88 at 36, 37, and 40 weeks after infection was the triply deleted variant that was also observed in the recovered virus from this same animal 12, 24, and 31 weeks after infection. Multiple amplifications with different sets of primers revealed by nucleotide sequence analysis smaller amounts of the original single nef-deletion and of variants with additional deletion of 111, 141, or 151 bp. Viral DNA was usually not detected from the PBMCs of animal 353-88 (Fig. 2) , but in the two reactions in which it was detect- ed both the original nef-deletion and additionally deleted variants were detected. Thus, sequences that correspond to wildtype nef-open challenge virus were not detected in any of the samples analyzed from the four test animals. Control animals 148-88, 246-90, and 388-90 showed declines in CD4' lymphocyte concentrations after the challenge, and by 36 weeks all control animals had either died (148-88 and 208-89) or had to be killed when moribund (388-90 and 246-90). All four previously vaccinated animals are still alive, healthy, and have shown no declines in CD4' lymphocyte concentrations.
At 37 weeks after the initial challenge, two of the test animals (71-88 and 255-88) were challenged with 1000 rhesus monkey infectious doses of the uncloned SIVmac251 stock. At weeks 3, 5, and 12 after this high-dose challenge, SIV was not recovered from their PBMCs even with the use of 106 cells, and PCR analysis revealed no evidence of wild-type nef-open challenge virus (Fig. 2) . Thus, early data suggest that these vaccinated monkeys may even be resisting high-dose challenge.
Rhesus monkeys vaccinated with SIVmac239/nef-deletion appear by all criteria used to have resisted challenge by wild-type pathogenic SIV. Previously vaccinated animals showed no evidence of plasma antigenemia at any time after challenge and maintained extremely low virus burdens as was observed before the challenge. Furthermore, genetic analysis of recovered virus and viral DNA present in their PBMCs revealed no evidence of wild-type, nef-open challenge virus. All four unvaccinated controls died, whereas all four previously vaccinated animals are alive and healthy and show no signs of the presence of wild-type virus. These are the most impressive protective effects we have seen in any of our vaccine experiments, including those experiments with inactivated whole virus (1), vaccinia recombinants expressing SIV env (9) , multivalent vaccinia recombinant expressing gag, pol, and env that can be assembled into SIV pseudovirion particles (9) , and multivalent vaccinia recombinant priming followed by SIV particle boosting (9).
We do not know the mechanisms that are responsible for the protective immunity observed in these experiments. In our previous vaccine experiments with vaccinia recombinant priming and SIV particle boosting, we were able to achieve neutralizing antibody titers that were 4 to 12 times higher on the day of challenge than those present in the monkeys vaccinated with SIV/nef-deletion (9 (4) (5) (6) . We have found that the stability of c-Fos is also regulated by phosphorylation of c-Jun. We expressed human c-Jun in HeLa and 293 cells to measure the stability of differentially phosphorylated forms of the c-Fosc-Jun heterodimer in an in vitro protein degradation assay. Tissue culture cells were transiently transfected with cytomegalovirus (CMV)-based plasmid vectors that encode a c-Jun derivative with an artificial hexahistidine sequence at its NH2-terminus that allows rapid purification (7, 8) while preserving the posttranslational phosphorylation of the protein (6) . This expression system yields a c-Jun protein (cmv-H6clun) that is phosphorylated in the TPA-responsive manner described for the endogenous
